Jerome Lemoine is a French transfection specialist who has completed his PhD thesis in the Center for Pharmacogenetics of the School of Pharmacy at the University of Pittsburgh in Leaf Huang’s lab from 2001 to 2005. He has pursued his scientific career in the field of transfection in Robert Debs’ lab in San Francisco, as a postdoctoral fellow.

Then, he has returned back to France, in order to perfect an in vivo messenger RNA delivery biotechnology and found a startup company.

After over three years of research, he has founded Messenger Biopharma in September 2015 whose President he is.

From April 2016 on, Messenger Biopharma’s R&D team has first invented a second-generation messenger RNA that is much cheaper than a traditional mRNA (Cf. Aegis™ biotechnology). Then, it discovered two approaches to reduce the concentration of dsRNA in mRNA solutions (Cf. Nuntius biotechnology).

Messenger Biopharma is housed by Biopôle Clermont Limagne in Riom, France.

OST Group, a company located in Saint-Beauzire, France, became a shareholder in July 2019.